Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
- Global Families Turn to Young Travelers Concierge Amid Rising Safety Concerns in the U.S
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
NAPERVILLE, Ill., Sept. 28, 2024 ~ Endotronix, a subsidiary of Edwards Lifesciences (NYSE: EW), has released the one-year clinical results from their PROACTIVE-HF study at the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The study evaluated the outcomes of using the Cordella Pulmonary Artery (PA) Sensor System in managing heart failure.
The data from the study showed that out of the 456 patients who were managed with Cordella, there was a significant reduction in one-year hospitalizations and all-cause mortality rate. This was compared to the pre-specified rate of 70 events per 100 patients, with only 36 events per 100 patients being reported in the study. This represents a 49% decrease in hospitalizations and mortality.
In addition to these primary endpoints, the study also looked at secondary endpoints such as quality of life and biomarker reduction. The results showed significant improvements in these areas as well. Patients experienced a 10.5% increase in their Kansas City Cardiomyopathy Questionnaire score, a 13.3% improvement in their 6-minute walk test distance, and a 36.2% decrease in New York Heart Association classification. There was also a 5.7% reduction in NT-proBNP levels, which is a biomarker for heart failure.
More on illi News
These findings further validate the previously published six-month data on the safety and efficacy of using Cordella for managing heart failure.
Dr. Liviu Klein, Section Chief of Advanced Heart Failure at the University of California San Francisco and national principal investigator of PROACTIVE-HF trial, commented on these results saying, "These data are consistent and compelling validating that PA pressure-guided therapy improves heart failure outcomes." He also noted that this trial adds to our understanding of how comprehensive data can improve outcomes by allowing for remote medical adjustments and engaging patients in their own care.
The study showed that by optimizing guideline-directed medical therapy and diuretics, clinicians were able to reduce PA pressures in congested patients, leading to improved heart function. One unique aspect of Cordella is that it provides patients with visibility into their health data, which can help drive their engagement and compliance with treatment.
Endotronix, which was acquired by Edwards Lifesciences, focuses on the intersection of medical technology and digital health to improve care for heart failure patients. Their comprehensive Cordella solution allows for proactive and data-driven management of heart failure, leading to better outcomes. The Cordella Sensor is an implantable device that directly measures PA pressure, a key indicator of congestion in heart failure patients.
To learn more about Endotronix and their innovative solutions for managing heart failure, visit www.endotronix.com.
The data from the study showed that out of the 456 patients who were managed with Cordella, there was a significant reduction in one-year hospitalizations and all-cause mortality rate. This was compared to the pre-specified rate of 70 events per 100 patients, with only 36 events per 100 patients being reported in the study. This represents a 49% decrease in hospitalizations and mortality.
In addition to these primary endpoints, the study also looked at secondary endpoints such as quality of life and biomarker reduction. The results showed significant improvements in these areas as well. Patients experienced a 10.5% increase in their Kansas City Cardiomyopathy Questionnaire score, a 13.3% improvement in their 6-minute walk test distance, and a 36.2% decrease in New York Heart Association classification. There was also a 5.7% reduction in NT-proBNP levels, which is a biomarker for heart failure.
More on illi News
- Mentor Agile Empowers Illinois Residents with Free Access To Product Management Training
- Midwest Pond Features & Landscapes Hits 100 Cleanouts This Spring, Expands Services Across Chicago
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Beyond Finance Wins Gold Stevie® Award for Customer Service Department of the Year in 23rd Annual American Business Awards
These findings further validate the previously published six-month data on the safety and efficacy of using Cordella for managing heart failure.
Dr. Liviu Klein, Section Chief of Advanced Heart Failure at the University of California San Francisco and national principal investigator of PROACTIVE-HF trial, commented on these results saying, "These data are consistent and compelling validating that PA pressure-guided therapy improves heart failure outcomes." He also noted that this trial adds to our understanding of how comprehensive data can improve outcomes by allowing for remote medical adjustments and engaging patients in their own care.
The study showed that by optimizing guideline-directed medical therapy and diuretics, clinicians were able to reduce PA pressures in congested patients, leading to improved heart function. One unique aspect of Cordella is that it provides patients with visibility into their health data, which can help drive their engagement and compliance with treatment.
Endotronix, which was acquired by Edwards Lifesciences, focuses on the intersection of medical technology and digital health to improve care for heart failure patients. Their comprehensive Cordella solution allows for proactive and data-driven management of heart failure, leading to better outcomes. The Cordella Sensor is an implantable device that directly measures PA pressure, a key indicator of congestion in heart failure patients.
To learn more about Endotronix and their innovative solutions for managing heart failure, visit www.endotronix.com.
Filed Under: Business
0 Comments
Latest on illi News
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Mayor Brandon Johnson Appoints Francisco Velez as Executive Director of the Chicago Office of Emergency Management and Communications
- Chicago City Council Passes Mayor Johnson's Landmark Green Social Housing Ordinance
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- Transfer Pricing Expert Andrew O'Brien-Penney Joins The Brattle Group as Principal
- Naperville Fire Department Invites Community Members to Fire Prevention Presentation on May 22
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- DR Instruments Inc Expands Lab Apparel Line with New 100% Cotton Lab Coats for Adults and Youth
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- Powerhouse Dynamics to Showcase Groundbreaking OilSmart by Open Kitchen® Solution at National Restaurant Association Show
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Naperville Welcomes Top Global Leaders Through Americas Competitiveness Exchange Visit
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway